Document Detail

Autologous cell therapies: challenges in US FDA regulation.
MedLine Citation:
PMID:  23210819     Owner:  NLM     Status:  In-Data-Review    
Cell-based therapies (CBTs) have been hailed for the last two decades as the next pillar of healthcare, yet the clinical and commercial potential of regenerative medicine has yet to live up to the hype. While recent analysis has suggested that regenerative medicine is maturing into a multibillion dollar industry, examples of clinical and commercial success are still relatively rare [1-3] . With 30 years of laboratory and clinical efforts fueled by countless billions in public and private funding, one must contemplate why CBTs have not made a greater impact. The current regulatory environment, with its zero-risk stance, stymies clinical innovation while fueling a potentially risky medical tourism industry. Here, we highlight the challenges the US FDA faces and present talking points for an improved regulatory framework for autologous CBTs.
Todd N McAllister; David Audley; Nicolas L'heureux
Related Documents :
12535249 - Efficacy and efficiency of new bacillus thuringiensis var israelensis and bacillus spha...
20597619 - Acupuncture in reproductive medicine.
20956609 - Using positive deviance for determining successful weight-control practices.
10286119 - Silver reclamation: management controls maximize yields.
24454289 - The growing use of herbal medicines: issues relating to adverse reactions and challenge...
19299259 - Tight budgetary control: a study of clinical department managers' perceptions in swedis...
23495119 - History of teaching anatomy in india: from ancient to modern times.
16582699 - Case managers' roles and functions: commission for case manager certification's 2004 re...
25262519 - Combination of flying needle with chinese herbal medicine in the treatment of atopic de...
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Regenerative medicine     Volume:  7     ISSN:  1746-076X     ISO Abbreviation:  Regen Med     Publication Date:  2012 Nov 
Date Detail:
Created Date:  2012-12-05     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  101278116     Medline TA:  Regen Med     Country:  England    
Other Details:
Languages:  eng     Pagination:  94-7     Citation Subset:  IM    
Cytograft Tissue Engineering, Inc., 3 Hamilton Landing, Suite 220, Novato, CA 94949, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Cell standardization: purity and potency.
Next Document:  Autologous cell therapies: the importance of regulatory oversight.